Literature DB >> 17296588

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.

Sylvain Choquet, Ralf Trappe, Veronique Leblond, Ulrich Jäger, Frederic Davi, Stephan Oertel.   

Abstract

There is no definitive treatment for post-transplant lymphoproliferative disorder (PTLD) that does not respond to reduction of immunosuppression. With a median follow-up of 8.8 years, the current retrospective analysis of standard CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) in 26 adults with PTLD demonstrated an overall response rate of 65% and median overall and progression-free survivals of 13.9 and 42 months, respectively.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17296588     DOI： 10.3324/haematol.10595

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  32 in total

Review 1.  Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder.

Authors:  Ajay Major; Manali Kamdar
Journal:  Curr Treat Options Oncol       Date:  2018-05-24

Review 2.  How I treat EBV lymphoproliferation.

Authors:  Helen E Heslop
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

3.  Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.

Authors:  Aaron S Rosenberg; Andreas K Klein; Robin Ruthazer; Andrew M Evens
Journal:  Am J Hematol       Date:  2016-04-26       Impact factor: 10.047

Review 4.  Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.

Authors:  Deepa Jagadeesh; Bruce A Woda; Jacqueline Draper; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2012-03

5.  Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Michael Uhlin; Helena Wikell; Mikael Sundin; Ola Blennow; Markus Maeurer; Olle Ringden; Jacek Winiarski; Per Ljungman; Mats Remberger; Jonas Mattsson
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

6.  Impact of the posttransplant lymphoproliferative disorder subtype on survival.

Authors:  Jean L Koff; Jing-Xia Li; Xinyan Zhang; Jeffrey M Switchenko; Christopher R Flowers; Edmund K Waller
Journal:  Cancer       Date:  2018-03-26       Impact factor: 6.860

7.  Rituximab, Dexamethasone, Cytarabine, and Cisplatin as Effective Platinum-Based Salvage Chemotherapy for Periportal Posttransplant Lymphoproliferative Disorder After an Orthotopic Liver Transplant.

Authors:  Eliza W Beal; Shaylyn Bennett; Latifa Sage Silski; Bryan Whitson; Mitchell Henry; Sylvester Black
Journal:  Exp Clin Transplant       Date:  2014-09-03       Impact factor: 0.945

8.  Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

Authors:  Andrew M Evens; Kevin A David; Irene Helenowski; Beverly Nelson; Dixon Kaufman; Sheetal M Kircher; Alla Gimelfarb; Elise Hattersley; Lauren A Mauro; Borko Jovanovic; Amy Chadburn; Patrick Stiff; Jane N Winter; Jayesh Mehta; Koen Van Besien; Stephanie Gregory; Leo I Gordon; Jamile M Shammo; Scott E Smith; Sonali M Smith
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

Review 9.  Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now?

Authors:  Daan Dierickx; Nina Cardinaels
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

10.  Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.

Authors:  T G Gross; M A Orjuela; S L Perkins; J R Park; J C Lynch; M S Cairo; L M Smith; R J Hayashi
Journal:  Am J Transplant       Date:  2012-08-06       Impact factor: 8.086
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.